Kinase chemodiversity from the Arctic: the breitfussins

This document is the Accepted Manuscript version of a Published Work that appeared in final form in Journal of Medicinal Chemistry, copyright © American Chemical Society after peer review and technical editing by the publisher. To access the final edited and published work see [insert ACS Articles o...

Full description

Bibliographic Details
Published in:Journal of Medicinal Chemistry
Main Authors: Østnes Hansen, Kine, Andersen, Jeanette hammer, Bayer, Annette, Pandey, Sunil Kumar, Lorentzen, Marianne, Jørgensen, Kåre Bredeli, Sydnes, Magne Olav, Guttormsen, Yngve, Baumann, Matthias, Koch, Uwe, Klebl, Bert, Eickhoff, Jan, Haug, Bengt Erik, Isaksson, Johan, Hansen, Espen
Format: Article in Journal/Newspaper
Language:English
Published: American Chemical Society 2019
Subjects:
Online Access:https://hdl.handle.net/10037/17555
https://doi.org/10.1021/acs.jmedchem.9b01006
Description
Summary:This document is the Accepted Manuscript version of a Published Work that appeared in final form in Journal of Medicinal Chemistry, copyright © American Chemical Society after peer review and technical editing by the publisher. To access the final edited and published work see [insert ACS Articles on Request author-directed link to Published Work, see https://doi.org/10.1021/acs.jmedchem.9b01006. In this work, we demonstrate that the indole-oxazole-pyrrole framework of the breitfussin family of natural products is a promising scaffold for kinase inhibition. Six new halogenated natural products, breitfussin C–H (3 – 8) were isolated and characterized from the Arctic, marine hydrozoan Thuiaria breitfussi. The structures of two of the new natural products were also confirmed by total synthesis. Two of the breitfussins (3 and 4) were found to selectively inhibit the survival of several cancer cell lines, with the lowest IC50 value of 340 nM measured against the drug-resistant triple negative breast cancer cell line MDA-MB-468, while leaving the majority of the tested cell lines not or significantly less affected. When tested against panels of protein kinases, 3 gave IC50 and Kd values as low as 200 and 390 nM against the PIM1 and DRAK1 kinases, respectively. The activity was confirmed to be mediated through ATP competitive binding in the ATP binding pocket of the kinases. Furthermore, evaluation of potential off-target and toxicological effects, as well as relevant in vitro ADME parameters for 3 revealed that the breitfussin scaffold holds promise for the development of selective kinase inhibitors.